Which of the following is true regarding sarcoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sarcoma Facts: Identifying the True Statement

Kaposi sarcoma is a common cause of death in patients with AIDS. This is the correct statement among the given options 1.

Analysis of Each Option

A. Kaposi sarcoma is a common cause of death in patients with AIDS

  • Kaposi sarcoma (KS) represents the most frequent tumor arising in HIV-infected individuals, particularly homosexual and bisexual men 1
  • The epidemic form of KS (AIDS-associated) occurs in up to 30% of HIV-1 infected individuals 1
  • AIDS-KS is aggressive and often results in dissemination and invasion of lymph nodes and viscera, contributing significantly to mortality in AIDS patients 1
  • KS is specifically mentioned in multiple sarcoma guidelines, highlighting its clinical significance in AIDS patients 2

B. Embryonal subtype is a rare childhood rhabdomyosarcoma

  • This statement is false. The ESMO guidelines specifically mention that embryonal rhabdomyosarcoma is not rare but rather common in children 2
  • The guidelines state: "Embryonal and alveolar rhabdomyosarcoma are exceedingly rare in adults" but does not indicate embryonal type is rare in children 2
  • In fact, embryonal rhabdomyosarcoma is one of the most common soft tissue sarcomas in the pediatric population 2

C. Embryonal subtype has the worst prognosis in childhood rhabdomyosarcoma

  • This statement is false. The alveolar subtype, not the embryonal subtype, generally has a worse prognosis in childhood rhabdomyosarcoma 2
  • The ESMO guidelines distinguish between embryonal and alveolar rhabdomyosarcoma, with different treatment approaches reflecting their different prognostic implications 2

D. Osteosarcoma arises from stromal cells

  • This statement is false. Osteosarcoma arises from primitive bone-forming mesenchymal cells, not stromal cells 2
  • Osteosarcoma is characterized by the production of osteoid (immature bone) by malignant cells 2
  • The ESMO-EURACAN-GENTURIS-ERN PaedCan bone sarcomas guidelines clearly define osteosarcoma as a primary malignant bone tumor 2

E. Osteosarcoma is one of the rarest malignant bone tumors

  • This statement is false. Osteosarcoma is actually the most common primary malignant bone tumor, not one of the rarest 2
  • According to the ESMO bone sarcoma guidelines, "OS is the first primary cancer of bone (incidence: 0.3 per 100 000 per year)" 2
  • The incidence is even higher in adolescents (0.8–1.1 per 100 000 per year at age 15–19 years) 2

Key Points About Kaposi Sarcoma

  • Kaposi's sarcoma is a tumor of mesenchymal origin that is strongly associated with HIV infection 1
  • It is characterized by mixed cellularity, spindle cells proliferation, and neoangiogenesis 1
  • The HIV-1 Tat protein acts as a growth factor for cells derived from AIDS-KS lesions, establishing an experimental link between HIV-1 infection and the development of KS in humans 1
  • KS is considered a cytokine-mediated disease with interactions between mesenchymal cell types and HIV-1 gene products 1
  • Due to its aggressive nature and tendency to disseminate in AIDS patients, it represents a significant cause of morbidity and mortality in this population 1

References

Research

Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma.

Advances in experimental medicine and biology, 1991

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.